Lisata Therapeutics announced that the European Medicines Agency, EMA, Committee for Orphan Medicinal Products has granted orphan drug designation to LSTA1, the Company’s lead product candidate for the treatment of pancreatic cancer. Currently, LSTA1 is the subject of multiple ongoing and planned clinical studies being conducted globally in a variety of solid tumor types, including pancreatic cancer, in combination with a variety of anti-cancer regimens. “Pancreatic cancer has one of the highest mortality rates of all cancers and affects hundreds of thousands of patients worldwide each year. Although progress has been made in understanding and treating pancreatic cancer, there remains significant unmet medical need,” stated Kristen K. Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of Lisata. “To date, LSTA1 has demonstrated favorable safety, tolerability, and activity to enhance delivery of standard-of-care chemotherapy for patients with metastatic pancreatic cancer. Obtaining orphan drug designation from the EMA reinforces our belief that LSTA1 offers major improvement in treating patients with this terrible disease. We are excited by the promise of LSTA1 for the treatment of pancreatic cancer and other solid tumors and are committed to advancing our development programs with the goal of providing a benefit to patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LSTA:
- Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer
- Lisata Therapeutics Announces Participation in Upcoming Conferences in October
- Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors
- Lisata Therapeutics announces first patient treated in BOLSTER trial
- Lisata Therapeutics says IDSMC recommends study continuation of ASCEND trial